Pilot Study of Haplo-Identical Natural Killer Cell Transplantation for Acute Myeloid Leukemia

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Protocol

NKAML: Pilot Study of Haplo-Identical Natural Killer Cell Transplantation for Acute Myeloid Leukemia

Diseases

Leukemias / Lymphomas : Acute myeloid leukemia

Description

At this time approximately 50 percent of children affected by acute myeloid leukemia (AML) are cured. Most of these patients with AML get into remission (cancer cells are wiped out) after one to three courses of induction therapy (initial intensive course of chemotherapy that is designed to wipe out cancer cells), but almost half of them relapse (cancer comes back). Also, despite improvements in supportive care, treatment-related issues and severe illnesses are still a problem. Therefore, the overall goal of our program is to develop new treatments that will overcome drug resistance, decrease relapse rates, and decrease the short-and long-term harmful effects of treatment. This study will evaluate a new form of therapy that includes NK cells and chemotherapy. NK cells are special cells in our immune system that specifically target cancer cells and cells that are infected by viruses. Studies in animals showed that NK cells may help donor cells to grow may reduce the chance of a condition called graft versus host disease (GVHD), and may reduce the chance of relapse.

Objectives

To find out if treating with NK cells is possible and safe in research participants with AML.
To study the blood and bone marrow of research participants who have received this treatment to find out more about this treatment.
To find out if NK cell transplantation will be an effective treatment.

Eligibility

Participant must have adequate liver, kidney, heart and lung function.
Female participant cannot be pregnant and must have a negative urine pregnancy test.
Female of child-bearing potential and males must agree to use adequate contraception for the duration of the study.
Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact

Jeffrey E. Rubnitz, MD, PhD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article